BRPI0510882A - epìtopes lipopolisacarìdeos de núcleo interno conservado como candidatos de espécie de vacina: epìtopes lipopolisacarìdeos de núcleo interno como candidatos de vacina para a prevenção de doenças causadas por patogêneses bacterianas veterinárias incluindo actinobacillus pleuropneumoniae, mannheimia haemolytica e pasteurella multocida - Google Patents
epìtopes lipopolisacarìdeos de núcleo interno conservado como candidatos de espécie de vacina: epìtopes lipopolisacarìdeos de núcleo interno como candidatos de vacina para a prevenção de doenças causadas por patogêneses bacterianas veterinárias incluindo actinobacillus pleuropneumoniae, mannheimia haemolytica e pasteurella multocidaInfo
- Publication number
- BRPI0510882A BRPI0510882A BRPI0510882-9A BRPI0510882A BRPI0510882A BR PI0510882 A BRPI0510882 A BR PI0510882A BR PI0510882 A BRPI0510882 A BR PI0510882A BR PI0510882 A BRPI0510882 A BR PI0510882A
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine
- candidates
- epitopes
- inner core
- core
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Sustainable Development (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
EPìTOPES LIPOPOLISACARìDEOS DE NúCLEO INTERNO CONSERVADO COMO CANDIDATOS DE ESPéCIE DE VACINA: EPìTOPES LIPOPOLISACARìDEOS DE NúCLEO INTERNO COMO CANDIDATOS DE VACINA PARA A PREVENçãO DE DOENçAS CAUSADAS POR PATOGêNESES BACTERIANAS VETERINáRIAS INCLUINDO ACTINOBACILLUS PLEUROPNEUMONIAE, MANNHEIMIA HAEMOLYTICA E PASTEURELLA MULTOCIDA Um epítope oligosacarídeo de núcleo interno conservado que causa uma doença patogênica bactericida isolada, incluindo Actinobacilius pleuropneumoniae (Ap), Mannheimia haemolytica (Mh) e Pasteurella multocida (Pm), é descrito. Construção de um grupo mutante bactericida exclusivamente representando o epítope OS de núcleo interno conservado com uma estrutura exposta no fim tem permitido a identificação, produção e isolamento de um LPS de núcleo interno que é comum para todas os três organismos. Além disso, desde que são vacinas associadas, anticorpos provocados contra o LPS conservado de núcleo interno e glicoconjugados compreendendo o LPS de núcleo interno unido a um carregador imunogênico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002467329A CA2467329A1 (en) | 2004-05-14 | 2004-05-14 | Inner core lps epitopes and uses thereof |
US57148904P | 2004-05-17 | 2004-05-17 | |
PCT/CA2005/000745 WO2005111196A1 (en) | 2004-05-14 | 2005-05-16 | Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0510882A true BRPI0510882A (pt) | 2007-12-26 |
Family
ID=35394157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0510882-9A BRPI0510882A (pt) | 2004-05-14 | 2005-05-16 | epìtopes lipopolisacarìdeos de núcleo interno conservado como candidatos de espécie de vacina: epìtopes lipopolisacarìdeos de núcleo interno como candidatos de vacina para a prevenção de doenças causadas por patogêneses bacterianas veterinárias incluindo actinobacillus pleuropneumoniae, mannheimia haemolytica e pasteurella multocida |
Country Status (8)
Country | Link |
---|---|
US (1) | US7759070B2 (pt) |
EP (1) | EP1747262B1 (pt) |
JP (1) | JP2007537307A (pt) |
AU (1) | AU2005243548A1 (pt) |
BR (1) | BRPI0510882A (pt) |
CA (1) | CA2565247C (pt) |
HU (1) | HUP0700044A2 (pt) |
WO (1) | WO2005111196A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008013735A2 (en) * | 2006-07-21 | 2008-01-31 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid |
WO2009108168A2 (en) * | 2007-11-12 | 2009-09-03 | Stein Daniel C | Gold nanoparticle glycoconjugates for generating igg specific for the carbohydrate |
CN102120028B (zh) * | 2011-03-09 | 2013-05-22 | 河南科技大学 | 从禽多杀性巴氏杆菌提取脂多糖并制作脂多糖疫苗的方法 |
JP6088489B2 (ja) | 2012-03-22 | 2017-03-01 | 一般財団法人化学及血清療法研究所 | Lpsワクチン |
TWI715617B (zh) * | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA01006106A (es) | 1998-12-15 | 2003-07-21 | Exiqon As | Acoplamiento de carbohidratos derivados de lipopolisacaridos en superficies solidas. |
ES2284681T3 (es) * | 2000-08-25 | 2007-11-16 | Aventis Pasteur Limited | Epitopos de oligosacaridos del nucleo de lipopolisacaridos de maemophilus influenzae como vacunas para la prevencion de infecciones por haemophilus influenzae. |
ES2320334T3 (es) * | 2002-02-22 | 2009-05-21 | National Research Council Of Canada | Uso de analogos de acidos grasos para el tratamiento y/o prevencion de enfermedades proliferativas de la piel. |
-
2005
- 2005-05-16 WO PCT/CA2005/000745 patent/WO2005111196A1/en active Application Filing
- 2005-05-16 US US11/569,093 patent/US7759070B2/en not_active Expired - Fee Related
- 2005-05-16 AU AU2005243548A patent/AU2005243548A1/en not_active Abandoned
- 2005-05-16 JP JP2007511818A patent/JP2007537307A/ja active Pending
- 2005-05-16 CA CA2565247A patent/CA2565247C/en not_active Expired - Fee Related
- 2005-05-16 HU HU0700044A patent/HUP0700044A2/hu unknown
- 2005-05-16 EP EP05745406A patent/EP1747262B1/en not_active Not-in-force
- 2005-05-16 BR BRPI0510882-9A patent/BRPI0510882A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1747262A1 (en) | 2007-01-31 |
AU2005243548A1 (en) | 2005-11-24 |
CA2565247A1 (en) | 2005-11-24 |
EP1747262A4 (en) | 2009-02-11 |
HUP0700044A2 (en) | 2009-03-30 |
US20080008723A1 (en) | 2008-01-10 |
WO2005111196A1 (en) | 2005-11-24 |
US7759070B2 (en) | 2010-07-20 |
JP2007537307A (ja) | 2007-12-20 |
CA2565247C (en) | 2014-03-25 |
EP1747262B1 (en) | 2012-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0510882A (pt) | epìtopes lipopolisacarìdeos de núcleo interno conservado como candidatos de espécie de vacina: epìtopes lipopolisacarìdeos de núcleo interno como candidatos de vacina para a prevenção de doenças causadas por patogêneses bacterianas veterinárias incluindo actinobacillus pleuropneumoniae, mannheimia haemolytica e pasteurella multocida | |
RU2008138702A (ru) | Способы и композиции для вакцинации домашней птицы | |
BRPI0620193B8 (pt) | composição imunogênica e vacina a compreendendo, bem como processo para preparar a vacina | |
BRPI0813307C1 (pt) | composição imunogênica, vacina, e, processo para fabricar a vacina | |
MX2010003202A (es) | Metodo para producir virus de la gripe. | |
TNSN07387A1 (en) | C.perfringens alpha toxoid vaccine | |
ES2663872T3 (es) | Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria | |
CR8638A (es) | Vacuna agalactiae estreptococos | |
MA32819B1 (fr) | Vaccin combine notamment contre la coqueluche acellulaire | |
EA201001479A1 (ru) | Вакцина | |
ATE491720T1 (de) | Impfstoff gegen pasteurella multocida | |
RU2017124240A (ru) | СПОСОБ ПОЛУЧЕНИЯ ГОТОВОЙ К ПРИМЕНЕНИЮ КОМБИНИРОВАННОЙ ВАКЦИНЫ ПРОТИВ PCV2/M.hyo | |
CL2008003845A1 (es) | Vacuna que comprende una emulsion, una bacterina tratada termicamente a 55-70°c por 5-10 horas, que comprende una suspension de bacterias muertas de la especie leptospira bratislava, y de 1 a 13 virus causantes de enfermedad porcina. | |
WO2007140244A3 (en) | Vaccination of young animals against lawsonia intracellularis infections | |
BR0112497A (pt) | Antìgenos de streptococcus pyogenes | |
RU2020109137A (ru) | Вакцина для защиты от streptococcus suis | |
WO2018083490A3 (en) | Capped oligosaccharides comprising seven or more units of 4,6-dideoxy-4-acylamido-alpha-pyranose and conjugates thereof as vaccines against infections caused by brucella organisms | |
Nicholas | The veterinary significance of mycoplasmas | |
BR0316687A (pt) | Composição e adjuvante vacinal e método para a obtenção de estruturas cocleares a partir de vesìculas de membrana externa de organismos vivos | |
NZ591738A (en) | Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella | |
BR112018015255A2 (pt) | extrato de streptococcus uberis como um agente imunogênico | |
BR112013010338A2 (pt) | composição, métodos para preparar uma composição imunogênica, para adjuvantar uma resposta imune, para eliciar uma resposta imune contra um agente infeccioso, para evitar e/ou reduzir a deposição de amilóide ou doença de alzheimer em um indivíduo, e para tratar/reduzir/melhorar a infecção por uma agente infeccioso, uso de uma proteína, e, kit | |
YOO et al. | A case of localized skin infection due to Scedosporium apiospermum diagnosed by DNA sequencing of the internal transcribed spacer region | |
BRPI0518620A2 (pt) | compostos, composiÇço farmacÊutica, mÉtodo para preparar uma composiÇço, e, uso de um composto | |
AR061201A1 (es) | Vacunacion de animales jovenes contra infecciones por lawsonia intracellularis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6 ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: C12N 1/36 (2006.01), A61K 31/739 (2006.01), A61K 3 |